The Worldwide Allergy Immunotherapy Market is Projected to reach USD 2.9 Billion by 2030, at a CAGR of 8.4%

Allergy Immunotherapy Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Allergy Immunotherapy Market size is expected to reach $2.9 billion by 2030, rising at a market growth of 8.4% CAGR during the forecast period.

The Hospital Pharmacy segment is showcasing a CAGR of 8.5% during (2023 - 2030). This is due to the increase in the number of patients seeking treatment for allergic diseases and the global hospitalization rate. Typically, allergy injections are administered at medical facilities or doctor's offices to track and manage any adverse effects. Thus, the segment expansion is further accelerated.

The Subcutaneous Immunotherapy (SCIT) segment is leading the Global Allergy Immunotherapy Market by Treatment Type in 2022; thereby, achieving a market value of $1.9 billion by 2030. The most efficient and popular type of allergen immunotherapy is SCIT. This therapy can treat asthma, stinging insect hypersensitivity, and allergic rhinitis effectively. Additionally, SCIT has shown success in managing a variety of allergens. Because of this, SCIT is used extensively than SLIT.

The Allergic Asthma segment is exhibiting a CAGR of 8.2% during (2023 - 2030). Allergy-related asthma is a respiratory disorder that results from allergies. The disorder known as allergic asthma causes the airways to constrict when one inhales an allergen. Pollen, dander, or mold spores are common airborne contaminants that could cause asthma. Feeling out of breath, frequent coughing, and other symptoms of asthma.

The Europe region dominated the Global Allergy Immunotherapy Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.1 billion by 2030. The North America region is exhibiting a CAGR of 8.1% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 9.4% during (2023 - 2030).

Full Report: https://www.kbvresearch.com/allergy-immunotherapy-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Viatris, Inc. (Mylan N.V.), Merck KGaA , NIOX Group plc , DMS Imaging SA, Adamis Pharmaceuticals Corporation, Stallergenes Greer International AG (B-Flexion), Allergy Therapeutics plc , DBV Technologies S.A., HAL Allergy B.V. (Droege International Group AG.), LETI Pharma, S.L.U.

Global Allergy Immunotherapy Market Segmentation

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

By Treatment Type

• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)
  • Tablets
  • Drops

By Allergy Type

• Allergic Rhinitis
• Allergic Asthma
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Viatris, Inc. (Mylan N.V.)
• Merck KGaA
• NIOX Group plc
• DMS Imaging SA
• Adamis Pharmaceuticals Corporation
• Stallergenes Greer International AG (B-Flexion)
• Allergy Therapeutics plc
• DBV Technologies S.A.
• HAL Allergy B.V. (Droege International Group AG.)
• LETI Pharma, S.L.U.

Related Reports:

North America Allergy Immunotherapy Market Size, Share, 2030

• July-2023
• 108 Pages

LAMEA Allergy Immunotherapy Market Size, Projection by 2030

• July-2023
• 121 Pages

Europe Allergy Immunotherapy Market Size & Share by 2030

• July-2023
• 120 Pages

Asia Pacific Allergy Immunotherapy Market Size & Share, 2030

• July-2023
• 121 Pages